CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,161 enrolled
Drug / intervention
Besifloxacin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00348348
NCT00348348Phase 3Completed
CompareCT.gov

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis

Bausch & Lomb Incorporated·interventional·Posted Jul 4, 2006·Updated Mar 24, 2015

In Brief

A Phase 3 clinical trial evaluating Besifloxacin and Moxifloxacin solution for Acute Bacterial Conjunctivitis. Completed, enrolled 1,161 participants.

Detailed Summary

This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Bacterial Conjunctivitis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2006
Enrollment StartJun 1, 2006
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.0 years ago

Interventions

Besifloxacindrug

Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days

Moxifloxacin solutiondrug

Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.